AstraZeneca Pharma India LimitedQ1 FY27 Results & Financial Update
AstraZeneca Pharma India Limited: Q1 FY27 standalone results and company financials – revenue ₹682.79 Cr, PAT ₹37.93 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
AstraZeneca Pharma India price & chart
Market price₹6,039.50
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore AstraZeneca Pharma India Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
AstraZeneca Pharma India Limited reported a strong financial and operational start for the quarter ended June 30, 2026, registering standalone revenue from operations of INR 682.79 crore (INR 6,827.9 million).
Company disclosures in related investor materials highlight a reported top-line growth of 30% year-on-year in absolute terms, supported by robust demand across core therapy areas including Oncology and Biopharmaceuticals.
Total income for Q1 FY27 reached INR 692.02 crore, incorporating other income of INR 9.23 crore. Profit before tax (PBT) before exceptional items stood at INR 50.99 crore, while the net profit after tax (PAT) for the quarter was reported at INR 37.93 crore.
The bottom line absorbed an exceptional item charge of INR 0.24 crore (net impact from restructuring or closure provisions), leading to a final PBT of INR 50.75 crore and a tax expense of INR 12.82 crore.
Therapy-wise performance reported by the company indicated that Oncology grew 26% year-on-year to INR 464.9 crore, Biopharmaceuticals (CVRM, R&I) expanded 36% to INR 161.9 crore, and Rare Diseases registered significant growth to INR 14.4 crore.
Operationally, the quarter was marked by key regulatory approvals for major therapies such as Acalabrutinib and Trastuzumab deruxtecan, alongside strategic public-private initiatives aimed at early disease screening and advanced clinical training in India.
Profit after tax was ₹37.93 Cr for the reported quarter. EPS was ₹0.00 for the reported quarter.
01 · Business model
What does AstraZeneca Pharma India do?
AstraZeneca Pharma India Limited (AZPIL) operates as the listed Indian subsidiary and operating company of the global science-led biopharmaceutical enterprise AstraZeneca.
The company engages in the discovery, development, and commercialization of specialized prescription medicines across key therapeutic verticals, primarily spanning Oncology, Biopharmaceuticals (covering cardiovascular, renal, metabolism, respiratory, and immunology), and Rare Diseases.
AZPIL serves patients nationwide through a workforce of over 600 employees, driving commercial execution and building strategic partnerships across the Indian healthcare ecosystem.
The economic model relies on importing, marketing, and distributing innovative proprietary formulations, supported by local manufacturing infrastructure and collaborative medical engagement initiatives.
02 · Historical context
What shaped the business before this quarter
During an earlier financial year, the company announced its intention to exit its manufacturing site in Bangalore and subsequently began exploring options to sell the site to operate as a Contract Manufacturing Organization (CMO).
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹682.79 Cr |
| Total income | ₹692.02 Cr |
| Profit before tax | ₹50.75 Cr |
| Profit after tax | ₹37.93 Cr |
| EPS | ₹0.00 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue expansion was propelled by sustained volume growth and prescriber adoption across Oncology, Biopharmaceuticals (CVRM and R&I), and Rare Disease portfolios.
What drove margins
The company recorded purchase of stock-in-trade at INR 304.62 crore and changes in inventories of finished goods, work-in-progress, and stock-in-trade showing a positive swing of INR 142.59 crore.
Employee benefit expenses stood at INR 79.16 crore, while selling, marketing, and distribution expenses were controlled at INR 30.75 crore and other expenses totaled INR 74.13 crore.
Depreciation and amortization expenses were reported at INR 5.23 crore, and finance costs were contained at INR 1.95 crore for the quarter.
05 · Demand, customers & order book
Where demand is coming from
The company expanded its market reach through clinician-led initiatives and scientific partnerships, including the launch of 'K+ Connect' for hyperkalaemia management and 'India Coronary Conquest 2026'.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates in a single primary business segment representing 'Healthcare', in accordance with Ind AS 108 ('Operating Segments'), reflecting its integrated pharmaceutical activities.
Geography and market mix
Sales and marketing efforts remained concentrated within the Indian domestic healthcare market, supplemented by regional collaborations such as the MoU signed with the Government of Telangana.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Manufacturing operations at the Bangalore plant remained ceased following decisions finalized in prior periods, with ongoing efforts directed toward asset monetization or transition to a CMO model.
Projects, capex and execution
Management commentary emphasized continued strategic investments in capability building, diagnostic access infrastructure, and digital health partnerships rather than traditional plant capacity expansion.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Signed an MoU with the Government of Telangana to deploy Qure.ai’s AI-powered chest X-ray solutions across 20 public health facilities for early lung cancer screening and risk identification.
Launched 'K+ Connect' to improve multidisciplinary risk identification and management of hyperkalaemia in heart failure and chronic kidney disease patients.
09 · Reported developments
What changed operationally
Secured key regulatory approvals including Acalabrutinib for chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL), as well as Trastuzumab deruxtecan for HER2-positive breast cancer.
Received the Medical Excellence Award for Rare Diseases and Runner-up in Marketing Excellence at the OPPI India Awards 2026, alongside the Gold Award at the ETHRWorld Employee Experience Awards 2026.
10 · Pressure points & risks
What is not going smoothly
Subsequent to the quarter end, the company received an order from the National Pharmaceutical Pricing Authority (NPPA) demanding INR 148.58 million (including interest) for alleged overcharging on a combination respiratory drug between May 2016 and November 2025; management is legally challenging the order.
Received a third-party demand of INR 10.00 crore in July 2026 relating to commercial lease losses, treated as a non-adjusting event after evaluation.
11 · Items worth noticing
The line items that can distort a quick read
Recorded an exceptional net credit/expense adjustment of INR (0.24) crore for Q1 FY27, primarily associated with the closure and restructuring of the Bangalore manufacturing site.
12 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Working capital requirements were managed through normal operating cycles, reflecting inventory adjustments and trade payables associated with imported and distributed pharmaceutical formulations.
Capital allocation & funding
The company maintained a low-leverage balance sheet, with finance costs restricted to lease and other operational liabilities amounting to INR 1.95 crore for the quarter.
13 · Management guidance & targets
What management is targeting from here
Management noted that the Q1 performance builds on a track record of consistent double-digit growth over the last five years, reiterating a strategic focus on sustainable long-term value creation.
14 · Beyond the numbers
What changed beyond the numbers
Reported update
Board and Management Changes
Approved the appointment of Mr. Arun Krishna as an Additional Director (Non-Executive) effective August 17, 2026. Ms. Bhavana Agrawal resigned as CFO effective August 31, 2026, to assume a regional role within the AstraZeneca Group, and was re-designated from Executive Director to Non-Executive Director effective September 1, 2026.
15 · Previous-quarter changes
What changed since the previous quarter
Revenue from operations compared to the preceding quarter (Q4 FY26) moved from INR 578.61 crore to INR 682.79 crore, while PAT shifted from INR 44.88 crore to INR 37.93 crore.
16 · Key Q&A
The quarter, answered directly
What does AstraZeneca Pharma India do?
AstraZeneca Pharma India Limited (AZPIL) operates as the listed Indian subsidiary and operating company of the global science-led biopharmaceutical enterprise AstraZeneca.
What is the clearest takeaway from Q1 FY27?
AstraZeneca Pharma India Limited reported a strong financial and operational start for the quarter ended June 30, 2026, registering standalone revenue from operations of INR 682.79 crore (INR 6,827.9 million).
What drove revenue or demand?
Revenue expansion was propelled by sustained volume growth and prescriber adoption across Oncology, Biopharmaceuticals (CVRM and R&I), and Rare Disease portfolios.
What mattered most for margins or profitability?
The company recorded purchase of stock-in-trade at INR 304.62 crore and changes in inventories of finished goods, work-in-progress, and stock-in-trade showing a positive swing of INR 142.59 crore.
What changed operationally beyond the headline numbers?
Manufacturing operations at the Bangalore plant remained ceased following decisions finalized in prior periods, with ongoing efforts directed toward asset monetization or transition to a CMO model.
What is management guiding or targeting from here?
Management noted that the Q1 performance builds on a track record of consistent double-digit growth over the last five years, reiterating a strategic focus on sustainable long-term value creation.
17 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
18 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
NPPA Pricing Order Resolution: Monitor legal and regulatory developments regarding the NPPA demand of INR 148.58 million for alleged respiratory drug overcharging.
- 02
Manufacturing Site Monetization: Track progress on the disposal or conversion of the inactive Bangalore manufacturing facility assets.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.